Ramapuram CV 08/2016

Jayachandra Babu Ramapuram, B. Pharm., M. Pharm., Ph.D. Professor of Pharmaceutics, Department of Drug Discovery and Development Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA Phone: 334-844-8320, Fax: 334-844-8331 Email: [email protected] EDUCATION 2001-2005 1993-1998 1991-1993 1986-1990

Postdoctoral Research Associate, College of Pharmacy, Florida A&M University Ph.D. in Pharmaceutics: Banaras Hindu University, India M. Pharm. (Pharmaceutics): Banaras Hindu University, India B. Pharm. (Pharmaceutical Sciences): Madras Medical College, India

POSITIONS HELD 20162011-2016 2005-2011 2001-2005 1998-2001 1993-1998 1990-1991

Professor, Harrison School of Pharmacy, Auburn University Assoc. Professor with Tenure, Harrison School of Pharmacy, Auburn University Assistant Professor, Harrison School of Pharmacy, Auburn University Research Associate, College of Pharmacy, Florida A&M University Assistant Manager, Product Development, GlaxoSmithKline (India) Limited Senior Research Fellow, Banaras Hindu University, India Quality Control Chemist, Ponds (India) Limited, Pondicherry, India

AWARDS AND HONORS 2015: 2014: 2012: 2011: 2011: 2011: 2006: 2003: 1993 1991

Dean’s Excellence in Research Award by the Harrison School of Pharmacy President’s Outstanding Collaborative Units Award, Auburn University Faculty Research Excellence Award, Harrison School of Pharmacy (2 awards) Faculty Research Excellence Award, Harrison School of Pharmacy (2 awards) Outstanding Graduate Mentor Award, Auburn University Team Member of NSF-HBCU RISE program Davis Productivity Award, Prudent Financial, State of Florida AAPS Postdoctoral Fellow, American Association of Pharmaceutical Scientists Senior Research Fellowship for 5 years: University Grants Commission, India Junior Research Fellowship for 18 months: University Grants Commission, India

MEMBERSHIP IN THE PROFESSIONAL SOCIETIES 2003-2005: 2002-2003: 2004-2010: 2006-2007: 1995-Present: 2013-Present: 2002-Present:

Member, Society of Investigative Dermatology Member, American Chemical Society Member, Society of Toxicology Member, American Association of Colleges of Pharmacy Life-time Member, Indian Pharmaceutical Association Member, Controlled Release Society Member, American Association of Pharmaceutical Scientists

1

Ramapuram CV 08/2016

CONTRACT / GRANT SUPPORT Newgen Biopharma Corporation, Titusville, NJ: 12/2015 - 11/2018 Evaluation of ocular and topical nanoparticles: This project involves Evaluation of various ocular and topical nanoparticle based formulations of different pharmaceutical ingredients, optimization of analytical method and stability data generation. Jay Ramapuram (PI) Total Award: 252,655 (Indirect Cost: 81,942) Newgen Biopharma Corporation, Titusville, NJ: 04/2012 - 04/2016 Evaluation of topical nanoparticles: This project involves Evaluation of various topical nanoparticle based formulations of different pharmaceutical ingredients, optimization of analytical method and stability data generation. Jay Ramapuram (PI) Total Award: 478,014 (Indirect Cost: 141,750) U.S. Dept. of Education, Graduate Assistance in the Areas of National Need (GAANN), Fellowships in Biological and Pharmaceutical Engineering: 08/2012 to 07/2015 PI: M. Byrne; Collaborating Faculty: D. Riese, D. Martin, V. Petrenko, C. Roberts, J. Wower, R. Gupta, A. David, R. Arnold, J. Ramapuram. Period: 08/1/12-07/31/15; $824,532. National Science Foundation, RISE Program, Enhancement of Research and Educational Infrastructure in Materials Science and Engineering at Tuskegee University: 09/2011 to 08/2014 Biological and Pharmaceutical Applications of Calcium Nanoparticles Generated from Sea Shells and Egg Shells: Shaik Jeelani (Program Director), Heshmat A. Aglan (PI), Jay Ramapuram (PI), Legend Burge (PI), Pradosh K. Ray (PI), NSF-RISE Grant: 1,000,000 Jay Ramapuram (PI) Total Award: 120,000 (Indirect Cost: 33,080) Fera Pharmaceuticals, Locust Valley, NY: 12/2010 to 11/2011 Evaluation of Oral Solution of an Anti-Fungal Drug: This project involves Evaluation of various solution formulations of the pharmaceutical ingredient, optimization of analytical method and stability data generation. Jay Ramapuram (PI) Total Award: 102,000 (Indirect Cost: 33,800) CSP Technologies Inc, Auburn AL: 10/2010 to 09/2011 Determination of Leachable materials in Pharmaceutical Packing Materials Jay Ramapuram (PI) Total Award: 15,775 (Indirect Cost: 5,044) California North State College of Pharmacy (CNCP): 06/2010 -06/2011 Microneedle assisted transdermal iontophoresis Jay Ramapuram (PI); Total Award: $1,500 Siga Technologies, Inc., Corvallis OR: 08/2010 – 08/2011 Granulation characterization for tablet compression Jay Ramapuram (PI); Total Award: $11,522 (Indirect cost: $3,292) Nu Therapeutics, Hyderabad, India: 07/2008 – 12/2010 Fast Dispersing Strips: Physical Characterization. Jay Ramapuram (PI); Total Award: $8,000 (Indirect cost: $2,520) Avema Pharma Solutions, Doral FL: 05/2008 – 02/2009 Formulation of generic oral dosage forms Jay Ramapuram (PI); Total Award: $29,900 (Indirect cost: $9,420) 2

Ramapuram CV 08/2016

Novavax Inc, Malvern, PA: 07/2007 – 06/2008 Transdermal permeation studies on formulations for erectile dysfunction Jay Ramapuram (PI); Total Award: $4,000 (Indirect cost: $1,260) Midlothian Labs, Montgomery AL: 12/2007 – 07/2008 HPLC Assay of Isometheptane, Dochloralphenazone and Acetaminophen Tablets Jay Ramapuram (PI); Total Award: $1,460 (Indirect cost: $460) Novavax Inc, Malvern, PA: 01/2007 - 06/2008 Transdermal/transcorneal permeation studies on various drugs Jay Ramapuram (PI); Total Award: $9,340 (Indirect cost: $2,943) Xenoport Inc, Santa Clara CA: 04/2007 – 12/2007 XP 13512 SR tablet formulation analysis Jay Ramapuram (PI); Total Award: $11,000 (Indirect cost: $3,466) Novavax Inc, Malvern, PA: 05/2006 - 12/2006 Transdermal delivery of anti-histamine and estrogenic drugs Jay Ramapuram (PI); Total Award: $8,000 Florida A&M University Tallahassee: 09/2006 - 12/2006 Analysis of data on dermal micro dialysis of model penetrants Jay Ramapuram (PI); Total Award: $5,000 Midlothian Laboratories: 05/2010 – 07/2010 Perform literature search to find sample pharmaceutical formulations Jay Ramapuram (co-PI); Daniel Parsons (PI) Total award: $730 Midlothian Laboratories: 05/2009 – 07/2009 Perform literature search to find sample pharmaceutical formulations Jay Ramapuram (co-PI); Daniel Parsons (PI) Total award: $500 INTRAMURAL FUNDING: Total = 83,500 Auburn University Intramural Grants Program (AU-IGP): 05/2015 – 04/2017 Codelivery of Doxorubuicin and Ceramide as a Nanoparticle Based System Jay Ramapuram (PI), Robert Arnold (Co-I), Total Funds: $80,000 Deans Discovery Research Grant: 01/2010 to12/2010 Novel Neuroinflammatory inhibitors for Psoriasis Jay Ramapuram (PI), Total funds: $3,500 CONSULTANT WITH PHARMACEUTICAL COMPANIES: 2007-2010: Nu Therapeutics Pvt Ltd, Hyderabad, India, Consultant 2006-2009: Novavax Inc, Malvern, PA, Consultant 2012-Present: Newgen Biopharma Corp., Titusville, NJ, Product Dev. Consultant 2015-Present: Scientific Advisory Board, Newgen Biopharma Corp., Titusville, NJ

3

Ramapuram CV 08/2016

GRANT REVIEWER 2014: 2012-2015: 2012: 2009:

DOD CDMRP, Vision Care Products, Grant Review Study Section AACP-NIA New Investigator Award Grant Program NMRC [CBRG11nov106] National Medical Research Council, Singapore Stage 1 ARRA RC1 Grant applications ZRG1 OTC-K (58) in the Oncology-2 Translational Clinical IRG (OTC)

LIST COURSES TAUGHT TO PROFESSIONAL AND GRADUATE STUDENTS 20162007-present: 20162007-present: 2006-present: 2011-present 2007-present 2014-present 2007-present 2007-present

PYPS 5320, Pharmaceutics I (3 credit hr., 60%) PYPS 5330, Pharmaceutics II (3 credit hr., 50%) PYDI 5320 Contemporary Aspects of Pharmacy Practice III (2 Credit hr., 40%) PYDI 5320 Contemporary Aspects of Pharmacy Practice IV (2 Credit hr., 50%) PYDI 5090/5190/5290/5390/5490/5590, Pharmacy Practice Exp. (2 cr. hr., 50%) PYPS 7030 Drug Products and Biopharmaceutics (4 Credit hours, 40%) PYPS 7060 Formulation and Delivery of Protein & Peptides (3 Credit hr., 80%) PYPS 7050, Novel Dosage Forms (3 credit hours) PYPS 8960, Special Problems in Pharmacal Sciences (1-3 credit hr., 100%) PYPS 8930, Directed Readings in Pharmacal Sciences (1-3 credit hr., 100%)

LIST OF GRADUATE AND POSTDOCTORAL SCHOLARS SUPERVISED A. MAJOR OR CO-MAJOR PROFESSOR 2006-2008: Phillip Lee, M.S., Scientist, Novartis (2008-2010) 2007-2009: G. Chadha, M.S. (Auburn), Ph.D. (Rutgers Univ)., Currently Asst. Prof. at NEU 2009-2011: Jin Xiao, M.S., Formulation Scientist at Avema Pharma, Miami, FL 2007-2011: Dr. Sateesh Sathigari, Staff Fellow, US-FDA, Rockville MD 2009-2013: Dr. Kasturi Pawar: Associate Scientist at G&W Labs, Plainfield, NJ 2010-2014: Dr. Li Chen, Staff Fellow, US-FDA, Rockville MD 2012-2013: S. Zainuddihn, M.S., Discontinued 2014-2016: Hamad Alrbyawi, M.S. student, Auburn University 2012-Present: Phillip Lee, Doctoral student, Auburn University 2013-present: Mohammed Aldawsari, Doctoral student, Auburn University 2014-Present: Ahmed Alsarq, Doctoral student, Auburn University 2014-Present: Haley Porter, Doctoral student, Auburn University 2016-present: Hamad Alrbyawi, M.S., Doctoral student, Auburn University

B. COMMITTEE MEMBER 2006: 2006: 2007-2011: 2009-2013: 2008-2010: 2007-2010: 2007-2010:

Dr. Roger Graben, PhD, VP-Research at Kowa Pharmaceuticals Atresh Tata, Analytical Chemist at Invagen Pharmaceuticals Inc. Dr. Kariharan Thiruchelvan, Ph.D., Postdoctoral Fellow at University of Alabama Dr. Manuj Ahuja, Ph.D., Postdoctoral Fellow at Georgia Regents Health System Dr. Nydeia Wright, Ph.D., Scientist, Eglin Air Force Base, Orange Beach, FL Dr. Melinda Hemmingway, Ph.D., Engineer, Agilent Technologies, Austin TX Dr. Raj Chinnawar, Ph.D., Postdoctoral Fellow, Auburn University 4

Ramapuram CV 08/2016

2007-2010: Dr. Courtney Ober, Ph.D., Senior R&D Scientist, Evonik, Birmingham, AL 2011-2014: Dr. Diene Render, Ph.D., Project Manager, U.S. Nuclear Regulatory Commission 2013-present: Ben Nie, PhD Candidate, DDD, Harrison School of Pharmacy 2013-present: Mathew Eggert, PhD Candidate, DDD, Harrison School of Pharmacy 2015-present: Shanese Jasper, PhD Candidate, DDD, Harrison School of Pharmacy 2015-present: Joshua Davis, PhD Candidate, DDD, Harrison School of Pharmacy C. POSTDOCTORAL RESEARCH SCHOLARS 2012-2013: Dr. Himanshu Gutpa, Staff Scientist in the US-FDA 2013: Dr. Vanisree Mulabagal, Research Fellow, Dept. Civil Eng., Auburn University 2013-2015: Dr. Wanding Deng, Scientist in WuXi Labs, Shanghai, China. 2015-Present: Dr. Ranjeet Dash (specialized in bioanalysis) UNDERGRADUATE / PROFESSIONAL STUDENTS Summer 2006: Summer 2007: Summer 2008: 2009-2010: Fall 2006: Summer 2009: 2012-2013: Summer 2011: Summer 2011: Summer 2016:

Kristen Jones, DVM Student; College of Veterinary Medicine, AU Elizabeth Cox, DVM Student, College of Veterinary Medicine, AU. Reanna Stahl, DVM Student, College of Veterinary Medicine, AU. Charlotte Stewart, B. Chem. E –Undergraduate Research Scholarship Mira Patel, BS - Biomedical Science Namita Vashi, BS - Biomedical Science: Haley Porter, B. Chem. E., Currently enrolled as a doctoral student. Jazmine Wilder, BS Biomedical Science, Diana Lushington, M.S, Polymer and Fiber Engineering Makenzie Grant, B. Chem. E. Sturent, College of Engg., Auburn Univ.

DISSERTATION EXAMINER FOR FOREIGN UNIVERSITIES 2016: APJ Abdul Kalam Technical University, India 2015: Annamalai University, India 2010: The Tamilnadu Dr. MGR Medical University, India 2010: Sri Ramachandra University, India: 2009: UP Technical University, Lucknow, India 2008: Manipal University, India 2008: The Tamilnadu Dr. MGR Medical University, India 2007: The Tamilnadu Dr. MGR Medical University, India PROMOTION AND TENURE REVIEWER 2013: Temple University, School of Pharmacy 2014: University of Hawaii at Hilo, College of Pharmacy 2015: Roosevelt University, College of Pharmacy

5

Ramapuram CV 08/2016

INDUSTRIAL PHARMACY RESEARCH EXPERIENCE 2012-Present: Principal Investigator, Newgen Biopharma Corporation, Titusville, NJ: Assisted in the product development, stability data generation, preparation of protocols for the technology transfer and product launch. Various drug molecules (steroidal hormones, anti-inflammatories, corticosteroids, immune suppressants) were in the form of micellar nanoparticles for topical delivery was developed, and dossiers were prepared for the technology transfer. 1998-2001: Assistant Manager, Product Development, GlaxoSmithKline (India) Ltd: Developed dosage forms such as tablets, capsules, topical creams and ointments and liquid oral formulations (containing anti-bacterial, anti-malarial, antidiarrheal, anti-inflammatory agents and vitamins and nutritional supplements). Formulation Development  

Design the product, technology, manufacturing and packaging requirements. Review the active drug and excipient chemistry; design analytical specifications for raw material, packing material and finished product.  Manufacturing processes such as, dry mix, slugging, wet granulation, dry milling, blending, compression, coating and curing  Handling special materials (potent drugs) that require special training and expertise and manufacturing environment Scale up, pilot batches and technology transfers 

Collaborate with Analytical R&D, Regulatory Affairs, Quality Assurance, Manufacturing, and production planning divisions in planning and executing formulation development, scale up and pilot batch manufacturing.  Review the manufacturing process; inspect contract sites to determine the manufacturing requirement and suitability of the equipment. Coordinate with manufacturing and quality assurance departments and decide the necessary process modifications.  Prepare master files, determine the batch size and process, determine packaging configuration(s) for stability testing, conduct stability studies as per ICH guidelines, analyze stability data, interpret and present data and prepare product development report.  Trouble-shoot pilot scale batches and subsequent manufacturing batches. Major Accomplishments  Developed and launched five tablet and two liquid oral suspension formulations of different drug molecules and two OTC vitamin/ food products.  Successfully performed the manufacturing site transfer of six tablet and liquid formulations for local and exports market.  Successful in the development and pilot scale trials of five liquid injection formulations 1990-1991: Quality Control Chemist, Ponds (India) Limited, Pondicherry, India  Quality control and testing of raw materials and finished cosmetic products: Topical creams, talcum powers, soaps  Microbiological testing of raw materials and finished cosmetic products 6

Ramapuram CV 08/2016

BOOK CHAPTERS PUBLISHED Note: All publications have my name as “Babu RJ; “ Babu R. Jayachandra” “Jayachandra Babu” * denotes corresponding author 1. N Kanikkannan, RJ Babu (50% effort), Structure-Activity Relationship of Chemical Penetration Enhancers, In: Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Modification of the Stratum Corneum, Chapter: 4, Publisher: Springer-Verlag Berlin Heidelberg, 2016 pp. 39-54, ISBN: 978-3-662-47038-1 2. RJ Babu* (80% effort), L Chen, N Kanikkannan. Fatty Alcohols, Fatty Acids, and Fatty Acid Esters, In: Percutaneous Penetration Enhancers Chemical Methods in Percutaneous Penetration Enhancement: Modification of the Stratum Corneum, Chapter: 9, SpringerVerlag Berlin Heidelberg, 2016 pp. 133-150, ISBN: 978-3-662-47038-1 3. RJ Babu* (90% effort), L Chen, Pyrrolidones, In: Percutaneous Penetration Enhancers Chemical Methods in Percutaneous Penetration Enhancement: Modification of the Stratum Corneum, Chapter: 17, Publisher: Springer-Verlag Berlin Heidelberg, 2016 pp. 291-299, ISBN: 978-3-662-47038-1 4. RJ Babu (70% effort), RR Patlolla, M Singh, Methods of assessing skin irritation and sensitization of Jet Fuels. In: Jet Fuel Toxicology, First Edition 07/2010: chapter 8: pages 135-145; CRC Press., ISBN: 9781420080209 5. M Singh and RJ Babu (50% effort), Chromatography, Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott William and Wilkins, Chapter 33, 599-625, 2005 (70% contribution) 6. RJ Babu (70% effort), M Singh and N Kanikkannan, Fatty alcohols and fatty acids, In Percutaneous Penetration Enhancers, Volume 2. Smith, E. and Maibach, H.I., Eds., CRC Press, New York pp137-158, 2005. (70% contribution) 7. N Kanikkannan, RJ Babu (30% effort) and M Singh, Structure-activity relationship of chemical penetration enhancers, In Percutaneous Penetration Enhancers, Volume 2. Smith, E. and Maibach, H.I., Eds., CRC Press, New York, pp17-34, 2005. (30% contribution) ARTICLE LENGTH PUBLICATIONS 1. Render D, Samuel T, King H, Vig M, Jeelani S, Babu RJ, Rangari V. Biomaterial-Derived Calcium Carbonate Nanoparticles for Enteric Drug Delivery. Journal of Nanomaterials. 2016 Article ID: 3170248, 1-8. 2. Shah PS, Desai PR, Boakye CH, Patlolla R, Babu RJ (30% effort), Singh M*. Percutaneous delivery of α-melanocyte stimulating hormone for the treatment of imiquimod-induced psoriasis. J Drug Target. 2015 Nov 18:1-11, 5-year Impact Factor: 2.850 3. Aldawsari M, Chougule M, Babu RJ* (60% effort), Progress in Topical siRNA Delivery Approaches for Skin Disorders, Current Pharmaceutical Design, 2015, 21 (31), 4594-605. 5year Impact Factor: 3.504 4. Pawar KR, Mulabagal V, Smith F, Kolli Chandra S, Rangari Vijaya K, Babu RJ* (60% effort). Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatography 2015, 29(5):716-21. 5-year Impact Factor: 1.754 5. Pawar KR, Babu RJ* (70% effort). Lipid materials for topical and transdermal delivery of nanoemulsions. Crit Rev Ther Drug Carrier Syst 2014, 31(5):429-58. 5-year Impact Factor: 3.492 6. Paliwal R, Babu RJ (30% effort), Palakurthi S*. 2014. Nanomedicine Scale-up Technologies: Feasibilities and Challenges. AAPS PharmSciTech 2014 15(6):1527-34. 5-year Impact Factor: 2.344 7. Pawar KR, Smith F, Kolli CS, Babu RJ* (70% effort). Effect of Lipophilicity on Microneedle 7

Ramapuram CV 08/2016

Mediated Iontophoretic Transdermal Delivery Across Human Skin In Vitro. J. Pharm. Sci. 2013, 102(10):3784-91. 5-year Impact Factor: 3.065 8. Gupta H, Babu RJ* (70% effort). Transdermal delivery: product and patent update. Recent Pat. Drug Delivery Formulation 2013, 7(3):184-205. Impact Factor: n/a 9. Sathigari SK, Radhakrishnan VK, Davis VA, Parsons DL, Babu RJ* (70% effort). Amorphous-state characterization of efavirenz-polymer hot-melt extrusion systems for dissolution enhancement. J. Pharm. Sci. 2012, 101(9):3456-64. 5-year Impact Factor: 3.065 10. Kolli CS, Xiao J, Parsons DL, Babu RJ* (60% effort). Microneedle assisted iontophoretic transdermal delivery of prochlorperazine edisylate. Drug Dev. Ind. Pharm. 2012, 38(5):5716. 5-year Impact Factor: 1.943 11. Chen L, Ding Y, Wang Y, Liu X, Babu RJ (30% effort), Ravis WR, Yan W*. Codelivery of zoledronic acid and double-stranded RNA from core-shell nanoparticles. Int. J. Nanomed. 2012, 8:137-45. 5-year Impact Factor: 4.712 12. Chadha G, Sathigari S, Parsons DL, Babu RJ* (50% effort). In vitro percutaneous absorption of genistein from topical gels through human skin. Drug Dev. Ind. Pharm. 2011, 37(5):498-505. 5-year Impact Factor: 1.943 13. Babu RJ (50% effort), Brostow W, Fasina O, Kalogeras, IM, Sathigari S, Vassilikou-Dova A. Encapsulation of hydrophobic drugs in a copolymer: glass transition behavior and miscibility evaluation, Polymer Engineering and Science 2011 51 (8), 1456-1465. 5-year Impact Factor: 1.608 14. Sathigari SK, Ober CA, Sanganwar GP, Gupta RB and Babu RJ* (60% effort), Single‐step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement, J. Pharm. Sci., 2011 100 (7) 2952-2965. 5-year Impact Factor: 3.065 15. Babu RJ* (60% effort), Dayal PP, Pawar K, Singh M. Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J. Drug Targeting 2011,19(9):731-40. 5-year Impact Factor: 2.850 16. Pawar KR and Babu RJ* (70% effort), Materials for topical nanoparticle delivery, Critical Rev. Ther. Drug Carrier Syst., 2010, 27(5), 419-459. 5-year Impact Factor: 3.492 17. Sanganwar GP, Sathigari S, Babu RJ, Gupta RB*. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. Eur J Pharm Sci. 39(1-3): 164-174, 2010. 5-year Impact Factor: 3.463 18. Kolli CS, Chadha G, Xiao J, Parsons DL, Babu RJ* (60% effort). Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro. J Drug Target. 2010, 18(9), 657-664. 5-year Impact Factor: 2.850 19. Babu RJ (50% effort), Brostow W, Kalogeras I, and Sathigari S, Glass transitions in binary drug + polymer systems: Concentration dependence, Materials Letters 2009, 63 (30), 26662668. 5-year Impact Factor: 2.466 20. Babu RJ* (60% effort), Sathigari S, Kumar MT, Pandit JK, Effect of Formulation and Process Variables on the Preparation of Amoxicillin Loaded Gellan Gum Beads, Current Drug Delivery 2010, 7(1): 36-43 Invited research paper, 2014 Impact Factor: 1.478 21. Mallampati R, Patlolla R, Agarwal S, Babu RJ* (40% effort), Hayden P, Klausner M, Singh M, Evaluation of EpiDerm Full Thickness-300 (EFT-300) as an In-Vitro Model for Skin Irritation: Studies on Aliphatic Hydrocarbons, Toxicology, In Vitro 2009, 24 (2) 669-671. 5year Impact Factor: 3.047 22. Kandimalla K, Babu RJ (40% effort), Singh M*, Biphasic Flux Profiles: The Yin-Yang of Transdermal Permeation Enhancement Mediated by Fatty Alcohol Enhancers, J. Pharm Sci, 2010, 99(1), 36-43 5-year Impact Factor: 3.065 23. Lee Y-H, Sathigari S, Lin Y-J, Ravis WR, Chadha GS, Parsons DL, Rangari V, Wright N, Babu RJ* (60% effort), Effect of cyclodextrin complexation on the improvement of solubility 8

Ramapuram CV 08/2016

and dissolution rate of Gefitinib, Drug Dev Ind Pharm. 2009 Sep;35(9):1113-1120. 5-year Impact Factor: 1.943 24. Patlolla RR, Mallampati R, Fulzele SV, Babu RJ (40% effort), Singh M, Dermal Microdialysis of Inflammatory Markers Induced by Aliphatic Hydrocarbons in Rats, Tox Lett, 2009, 185(3):168-174. 5-year Impact Factor: 3.545 25. Sathigari S, Chadha GS, Lee Y-H, Wright N, Parsons DL, Rangari VK, Fasina, Babu RJ* (50% effort), Effect of cyclodextrin complexation on the improvement of solubility and dissolution rate of Efavirenz. AAPS Pharm Sci Tech 2009 (10): 81-87. 5-year Impact Factor: 2.344 26. Babu RJ* (50% effort), Ravis WR, Duran SH, Schumacher J, Cox E, Stahl R, Jones K, Lin Y-J, Lee Y-H, Parsons DL, Portman EM, Brown SCR, Alkylurea as an enhancer for transdermal permeation of phenylbutazone across deer skin J. Vet. Pharmacol Ther, 2009 Aug; 32(4): 388-392. 5-year Impact Factor: 1.252 27. Babu RJ* (70% effort), Dhanasekaran M, Vaithiyalingam SR, Pandit JK, Cardiovascular effects of transdermally delivered bupranolol in rabbits: effect of chemical penetration enhancers, Life Sci. 2008, 82 (5-6): 273-278. 5-year Impact Factor: 2.670 28. Dhanasekaran M, Karuppagounder SS, Uthayathas S, Wold LE, Parameshwaran K, Babu RJ (20% effort), Suppiramaniam V, Brown-Borg H, Effect of dopaminergic neurotoxin MPTP/MPP+ on coenzyme Q content, Life Sci. 2008 Jul 18;83(3-4):92-95. 5-year Impact Factor: 2.670 29. Babu RJ (60% effort), Dayal P, Singh M, Effect of cyclodextrin complexation on the improvement of solubility and nasal permeation of melatonin. Drug Delivery 15: 381-388, 2008. 5-year Impact Factor: 2.111 30. Fulzele SV, Babu RJ (40% effort), Ahaghotu E, Singh M*, Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals, Toxicology 2007, 237(1-3):77-88. 5-year Impact Factor: 3.811 31. Chatterjee A, Babu RJ (40% effort), Klausner M, Singh M*, In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDerm (EPI-200) cultured human skin and hairless rats. Toxicol Lett. 2006 (167); pp 85-94. 5-year Impact Factor: 3.545 32. Kikwai L, Babu RJ (30% effort), Kanikkannan N, Singh M*, Degradation kinetics of Spantide II in aqueous solutions, Eur. J. Pharm. Sci. 27: 158-166, 2006. 5-year Impact Factor: 3.463 33. Kikwai L, Babu RJ (30% effort), Oliveira R, Armstrong CA, Ansel JC, Singh M*, In vitro and in vivo evaluation of topical formulations of Spantide II, AAPS PharmSciTech 2005, 6(4): E573-584. 5-year Impact Factor: 2.344 34. Dayal P, Pillay V, Babu RJ (30% effort), Singh M*, Box–Behnken Experimental Design in the Development of a Nasal Drug Delivery System of Model Drug Hydroxyurea: Characterization of Viscosity, In vitro Drug Release, Droplet Size and Dynamic Surface Tension, AAPS PharmSciTech 2005, 6(4): E565-572. 5-year Impact Factor: 2.344 35. Babu RJ* (80% effort), Pandit JK, Effect of penetration enhancers on the release and skin permeation kinetics of reservoir type transdermal delivery system of bupranolol. Int. J. Pharm. 288: 325-334, 2005. 5-year Impact Factor: 4.011 36. Babu RJ (50% effort), Kikwai L, Jaiani LT, Kanikkannan N, Armstrong CA, Ansel JC Singh M*, Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist - Spantide II, Pharm. Res. 21: 108-113, 2004. 5-year Impact Factor: 4.290 37. Babu RJ (50% effort), Kanikkannan N, Kikwai L, Ortega C, Andega S, Ball K, Yim S, Singh M*. The influence of various methods of cold storage of skin on the permeation of melatonin and nimesulide. J. Controlled Rel. 86:49-57, 2003. 5-year Impact Factor: 8.097 38. Babu RJ* (80% effort), Pandit JK, Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin, Int. J. Pharm. 271: 155-165, 2004. 5year Impact Factor: 4.011 39. Babu RJ* (80% effort), Pandit JK, Effect of penetration enhancers on the transdermal 9

Ramapuram CV 08/2016

delivery of bupranolol through rat skin, Drug Deliv. 12: 165-169, 2005. 5-year Impact Factor: 2.110 40. Babu RJ (50% effort), Chatterjee A, Singh M*, Percutaneous absorption, skin irritation, and biomarker responses by nonane, dodecane and tetradecane in hairless rats, Toxicol. Lett. 153: 255-266, 2004. 5-year Impact Factor: 3.545 41. Babu RJ (50% effort), Chatterjee A, Ahaghotu E, Singh M, Percutaneous absorption and skin irritation upon low level prolonged dermal exposures of nonane, dodecane and tetradecane in hairless rats, Toxicol. Ind. Health 20: 109-118, 2004. 5-year Impact Factor: 1.657 42. Chatterjee A, Babu RJ (40% effort), Ahaghotu E, Singh M*, The effect of occlusive and unocclusive exposures of xylene and benzene on skin irritation and molecular responses in hairless rats, Arch. Toxicol. 79: 294-301, 2005. 5-year Impact Factor: 4.933 43. Ahaghotu E, Babu RJ (40% effort), Chatterjee A, Singh M*, Effect of methyl substitution of benzene on the percutaneous absorption and skin irritation hairless rats, Toxicol. Lett. 159: 261-271, 2005. 5-year Impact Factor: 3.545 44. Kikwai L, Babu RJ (40% effort), Kanikkannan N, Singh M, Preformulation Stability of Spantide II, a Promising Topical Anti-inflammatory Agent for the Treatment of Psoriasis and Contact Dermatitis, J Pharm. Pharmacol. 56: 19-25, 2004. 5-year Impact Factor: 2.385 45. Kikwai L, Kanikkannan N, Babu RJ (40% effort), Singh M*. Effect of vehicles on the transdermal delivery of melatonin across porcine skin in vitro. J. Controlled Rel. 83:307-311, 2002. 5-year Impact Factor: 8.011 46. Kanikkannan N, Andega S, Burton S, Babu RJ (20% effort), Singh M*, Formulation and In Vitro Evaluation of Transdermal Patches of Melatonin, Drug Dev. Ind. Pharm. 30: 1-8, 2004. 5-year Impact Factor: 1.943 47. Babu RJ* (50% effort), Pandit JK, Effect of cyclodextrin complexation on the dissolution stability of glibenclamide tablets. Drug Dev. Ind. Pharm. 25(11) 1215-1219 (1999). 5-year Impact Factor: 1.943 48. Pandit JK*, Tripathi MK, Babu RJ (50% effort), Effect of tablet disintegrants on the dissolution stability of nalidixic acid tablets. Die Pharmazie 54 (7) 538-540 (1997). 5-year Impact Factor: 1.058 49. Pandit JK*, Mishra DN, RJ Babu (40% effort) and, Effect of diluents and disintegrants on the dissolution rate of directly compressed frusemide tablets. Indian Drugs 35 (5) 296-301 (1997). 50. Mishra DN, Babu RJ (40% effort), Wahi SP, Pandit JK*, Effect of Nymcel ZSB10 on the bioavailability of directly compressed frusemide tablets. Indian Drugs 32 (12) 592-593 (1995). 51. Venkateswari Y, Babu RJ (40% effort), Sampath Kumar D, Mittal N Pandit JK*, Development of a low cost tetracycline strip for long-term treatment of periodontal disease. Indian Drugs 32 (5) 205-210 (1995). 52. Babu RJ* (70% effort), Pandit JK, Enhancement of dissolution rate and hypoglycemic activity of glibenclamide by -cyclodextrin. STP Pharma Sci. (France) 5(3) 196-201 (1995). 5-year Impact Factor: 0.655 53. Sridevi S, Babu RJ (40% effort), Mittal N, Kumar DS, JK Pandit*, Development and evaluation of acrylic strips of metronidazole for the therapy of periodontal disease. Die Pharmazie 50 (2) 153-154 (1995). 5-year Impact Factor: 1.058 54. Renuka B, Babu RJ (40% effort), Wahi SP, Pandit JK*, Effect of fasting and stress on transdermal delivery of propranolol in rats. Die Pharmazie 49 (1) 75 (1994). 5-year Impact Factor: 1.058 55. Mishra DN, Wahi SP, Babu RJ (30% effort), Pandit JK*, Effect of some formulation variables on dissolution and bioavailability of frusemide tablets. Eastern Pharmacist (1994), 37(441), 121-4. 10

Ramapuram CV 08/2016

56. Choudhury PK, Pandit JK, Babu RJ (30% effort), Kumar, DS*, Effect of polyethylene glycol 6000 on the release of pentazocine from microcapsules. Eastern Pharmacist (1994), 37(439), 121-4. 57. Pandit JK*, Vemuri NM, Wahi SP, Babu RJ (30% effort), Mucosal dosage form of ephedrine hydrochloride using Gantrez AN 139. Eastern Pharmacist (1993), 36(428), 16970. 58. Tripathi MK, Babu RJ (40% effort), Wahi SP, Pandit JK*, Bile salt potentiation of solubility and wettability of nalidixic acid. Eastern Pharmacist (1993), 36(430), 127-8. 59. Babu RJ* (80% effort) Pandit JK, Cyclodextrin inclusion complexes for oral applications. Eastern Pharmacist (1995), 38(447), 37-42. Editor picked, cover future article RESEARCH MANUSCRIPTS SUBMITTED / IN PREPARATION 1. Ramani C, Rambhau D, Apte SS, Babu RJ, Effect of surface charge density of a w/o/w emulsion on the brain targeting of levodopa in Rats, J. Pharm. Sci (Submitted) 2. Pawar K, Render D, Parsons DL, Lee YY, Rangari V, Babu RJ* (50% effort), Evaluation of Non Crystalline Cellulose as an Excipient in Solid Dose Products, J. Pharm Sci. 3. Pawar K, Kolli C, Babu RJ* (60% effort), Microneedle assisted iontophoretic transdermal delivery of lysine-proline-valine peptide across human skin, Int. J. Pharm 4. Chen L, Ravis WR, Babu RJ* (60% effort): Codelivery of Doxorubuicin and Ceramide as a Nanoparticle Based System for Melanoma Treatment, Int. J. Nanomedicine 5. Chen L, Ravis WR, Babu RJ* (60% effort): Formulation of Genistein Microemulsion for Enhanced Transdermal Delivery, AAPS PharmsciTech 6. Chen L, Chougule M, Palakurthi S, Babu RJ* (50% effort), lipid based drug delivery systems for Melanoma Treatment, Critical Reviews in Therapeutic Carrier Systems 7. Babu RJ* (70% effort), Sathigari S, Shenoy D. Enhanced topical delivery of alprostadil using micellar nanoparticles (J. Drug Targeting) 8. Mulabagal V, Kurapati S, Wu Y, Babu RJ* (50% effort), Stability-indicating HPLC method for simultaneous determination of acyclovir and lidocaine in nanoemulsions Biomedical Chromatography PUBLISHED ABSTRACTS AND CONFERENCE PROCEEDINGS * presenting author; # corresponding author 1. EM Abarca*, R Cuming, S Duran, J Ramapuram. Development of an Ex-vivo trans-corneal permeation model in horses: Epithelial barrier evaluation, American College of Veterinary Ophthalmologists (ARVO) Annual Meeting, Invest. Ophthalmol. Vis. Sci. 2015; 56(7 ):4164 (30% contribution) 2. Chen L*, Ravis WR, Babu RJ#, Formulation of Genistein Nanoemulsions for Enhanced Cytotoxicity in Melanoma Treatment, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) San Diego, CA during November 02-06, 2014. Poster# M1134 (50% contribution) 3. Chen L*, Ravis WR, Babu RJ#, Co-delivery of Doxorubicin and Ceramide as a Nanoparticle Based System for the Treatment of Melanoma, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) San Diego, CA during November 02-06, 2014. Poster# M1133 (50% contribution) 4. Aldawsari M*, Chen L, Babu R#. Resveratrol Nanogel Formulation for Enhanced Transdermal Delivery across Human Skin, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) San Diego, CA during November 02-06, 2014. Poster# M1041 (50% contribution) 5. Lee Y-H*, Pawar K, Ravis W, Babu R#. Linear Pharmacokinetic Modelling to Describe the In 11

Ramapuram CV 08/2016

Vitro Transdermal Absorption of Beta-Blocker Drugs, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) San Diego, CA during November 02-06, 2014. Poster# M1223 (50% contribution) 6. Porter H, Chen L, Kurapati S, Mulabagal V, Ramapuram JB*#, Stability and Degradation Profiles of Betamethasone Diporpionate in Topical Nanoparticle Formulation, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) San Diego, CA during November 02-06, 2014, Poster# M1092 (50% contribution) 7. Mostafavi SH, Babu RJ (2013). Nano-Sized Drug Delivery. J Mol Pharm Org Process Res, 1, e108, pp 1-2 (editorial, 50% contribution) 8. Pawar K, Babu R*#, Kolli C, Transdermal Delivery of an Anti-inflammatory Peptide (KPV) across Dermatomed Human Skin, In Vitro, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2013, Poster# T2213. (50% contribution) 9. Chen L*, Ravis W, Babu R#. Formulation of Genistein Nanoemulsions for Enhanced Transdermal Delivery, In Vitro, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2013, Poster# T2245. (50% contribution) 10. Render D, Rangari V, Samuel T, Ramapuram J, Pawar, K, & Jeelani S. Development of Drug Delivery Sys-314 (30% contribution)tem Using Bio based Calcium carbonate Nanoparticles., Nanotech 2013: 3, 312 11. Sathigari SK*, Radhakrishnan V, Davis V, Parsons, DL, Ramapuram JB#, Efavirenz— Polymer Hot Melt Extrusion Systems for Dissolution Enhancement, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2012, Poster# R6288 (50% contribution) 12. Chen L*, Babu R#, Ravis W, Yan, W, Co-delivery of Zoledronic Acid and Double-strand RNA (dsRNA) from Core-shell Nanoparticles, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2012, Poster# T3195 (50% contribution) 13. Pawar K*, Kolli C, Babu R#, Effect of Lipophilicity of Drugs on the Iontophoretic Delivery across Microneedle Treated Human Skin. Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2012, Poster# R6329 (50% contribution) 14. Singh M*, Shah P, Desai P, Boakye C, Mallampati R, Fulzele S, Babu R. Enhanced Skin Permeation of alpha-melanocyte Stimulating Hormone for the Treatment of Inflammatory Skin Disorders, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2012, Poster# R6015 (50% contribution) 15. Chen L*, Ravis W, Babu R#. Stability and Degradation Profiles of Genistein Topical Nanoemulsions, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2012, Poster# R6071 (50% contribution) 16. Pawar K*, Kolli C, Babu R#, Stability and degradation profiles of Lys-Pro-Val (KPV) peptide in aqueous solutions, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2011, Poster# T2164 (50% contribution) 17. Pawar K*, Lee Y, Babu RJ#, Evaluation of non-crystalline cellulose as an excipient in solid dosage forms, Annual National Meeting of American Association of Pharmaceutical scientists (AAPS) 2011, Poster# W4227 18. Pawar K*, Dayal P, Singh M, Babu RJ#, Characterization of melatonin formulations for noseto-brain delivery, Pharmaceutical Sciences World Congress (PSWC) 2010, Poster# T3208 (50% contribution) 19. Pawar K*, Wright N, Rangari V, Babu RJ#, Preparation and Characterization of Chitosan Coated Magnetic Nanoparticles as Carriers of Paclitaxel, , Pharmaceutical Sciences World Congress (PSWC) 2010, Poster# M1341 (50% contribution) 20. Jin X*, Kolli C, Parsons D, Babu RJ#, Microneedle Assisted Iontophoretic Transdermal Delivery of Prochlorperazine, Pharmaceutical Sciences World Congress (PSWC) 2010, Poster# W4105 (50% contribution) 21. Sathigari S,* Ober C, Gupta R, Parsons D, Babu RJ#. Simultaneous Production and Co12

Ramapuram CV 08/2016

mixing of Itraconazole Micro/Nanoflakes with Stabilizers and Pharmaceutical Carriers by a Supercritical Antisolvent Method for Dissolution Enhancement, Pharmaceutical Sciences World Congress (PSWC) 2010, Poster# R6075 (50% contribution) 22. Sathigari S*, Radhakrishnan VK, Davis V, Parsons D, Ramapuram J.# Efavirenz - Polymer Hot Melt Extrusion Systems for Dissolution Enhancement: Physico-mechanical Characterization and Drug Release Studies, 39th Controlled Release Society Annual Meeting & Exposition, Québec City, Canada, Published in Proceedings, July 2012. (50% contribution) 23. CA Ober*, S Sathigari, G Sanganwar, JB Ramapuram, RB Gupta, Simultaneous Production and Co-Mixing of Itraconazole Nanoflakes with Stabilizers and Excipients by a Supercritical Antisolvent Method, for Dissolution Enhancement, 2010 AIChE Annual Meeting; 11/2010 (50% contribution) 24. G Sanganwar*, S Sathigari, JB Ramapuram, RB Gupta, Simultaneous Microparticle Formation and Mixing in Supercritical CO2. Fast-Release Navirapine Drug Formulation, 2009 AIChE Annual Meeting; 11/2009 (50% contribution) 25. S. Sathigari*, G. P. Sanganwar, R. B. Gupta, D. L. Parsons, R. Babu#, Enhancement of Dissolution by Simultaneous Crystallization of Poorly Soluble Drug and Mixing with Pharmaceutical Carrier(s) using the Supercritical Fluid Anti-Solvent Process. AAPS Journal, Vol. 11, No. S2, Abstract 3428 (2009) (50% contribution) (50% contribution) 26. R Mallampati*, RR Patlolla, RJ Babu, M Klausner, P Hayden, MS Sachdeva, Dermal irritancy of aliphatic hydrocarbons (C9-C14) using the in vitro EpiDerm full thickness (EFT300) skin model. The Toxicologist, Abstract 123, Vol 108 (1), March 2009 (30% contribution) 27. G Chadha*, S Sathigari, D Parsons, RJ Babu#, S Palakurthi, poster, “In Vitro percutaneous absorption of genistein from topical gel vehicles through human skin,” AAPS Journal, Vol. 10, No. S2, Abstract 3054 (2008) (50% contribution) 28. RJ Babu*#, Y-HP Lee, S Sathigari, G Chadha, D Parsons, D Shenoy, C Cox, R Lee, poster, “Evaluation of Nanoparticle Based Topical Formulations of Raloxefene, In vitro,” AAPS Journal, Vol. 10, No. S2, Abstract 2619 (2008) (50% contribution) 29. S Sathigari*, S Uthayathas, M Dhanasekaran, G Chadha, D Parsons, R Babu*#, D Shenoy, C Cox, R Lee, poster, “Micellar Nanoparticle Based Topical Formulations of Alprostadil: In vitro & In vivo Evaluation,” AAPS Journal, Vol. 10, No. S2, Abstract 2986 (2008) (50% contribution) 30. R Mallampati*, RR Patlolla, A Johnson, Y Lu, SV Fulzele, RJ Babu, C Armstrong, J. Ansel, MS Sachdeva, Anti-inflammatory activity of Alpha MSH formulations in ACD, model, AAPS Journal, Vol. 10, No. S2, Abstract 2535 (2008) (15% contribution) 31. Y-H Lee* and JB Ramapuram#, Enhancement of Solubility and Dissolution Rate of Gefitinib by Complexation with Cyclodextrins, AAPS Journal, Vol. 10, No. S2, Abstract 999 (2008) (60% contribution) 32. RR Patlolla, MB Chougule, J Samaan, R Mallampati, P Vashi, RJ Babu, MS Sachdeva, Encapsulation and in-vitro skin permeation of Spantide II encapsulated Nanolipid crystal (NLC) nanoparticles, AAPS Journal, Vol. 10, No. S2, Abstract 2388 (2008) (15% contribution) 33. R Babu*#, S Sathigari, G. Chadha, MT Kumar, J Pandit, “Effect of formulation variables on the preparation and drug release of amoxicillin loaded gellan gum beads” AAPS Journal, Vol. 10, No. S2, Abstract 3070 (2008) (60% contribution) 34. M Singh*, R Mallampati P Hayden, M Klausner, RR Patlolla, RJ Babu, Evaluation of Epiderm (EFT-300) as an in vitro model for skin irritation, The Toxicologist, Abstract 335, Vol 102 (1), March 2008 (40% contribution) 35. S Fulzele*, R. Mallampati, R. Babu, M. Singh, Preformulation stability, percutaneous absorption and topical antiinflammatory activity of alpha-melanocyte stimulating hormone for contact dermatitis AAPS Journal, Vol. 9, No. S2, Abstract 3405 (2007) (40% contribution) 13

Ramapuram CV 08/2016

36. S Fulzele*, R Babu E. Ahaghotu, M Singh, Investigation of Dermal irritation potential of selected Jet fuel chemicals (nonane, dodecane and tetradecane) by in vivo microdialysis, The Toxicologist, Abstract 2083, Vol 96 (1), March 2007 (40% contribution) 37. S Fulzele*, RJ Babu, E Ahaghotu and M. Singh. Dermal microdialysis of proinflammatory neurochemicals as markers of skin Irritation after exposure with jp-8 chemicals, The Toxicologist, Abstract 840, Vol 90 (1), March 2006 (40% contribution) 38. RJ Babu*#, A Chatterjee, S Fulzele, N Verma, M Singh, Effect of low level prolonged exposures of JP-8 on the biomarker expressions in the skin of Wistar rats, The Toxicologist, Abstract 177, Vol 90 (1), March 2006 (50% contribution) 39. M Singh, RJ Babu*#, A Chatterjee, S Fulzele, M. Klausner, J Kubilus, Evaluation of Epiderm as a model to study irritation after exposure to various aliphatic hydrocarbons found in jet fuels, The Toxicologist, Abstract 1591, Vol 90 (1), March 2006 (30% contribution) 40. M Singh, S Fulzele, RJ Babu*, L Kikwai, R Prado, Y Lu, C Armstrong, J Ansel, Percutaneous Absorption and Anti-inflammatory effect of alpha-melanocyte stimulating hormone, AAPS Journal, Vol. 8, No. S2, Abstract M1185 (2006) (20% contribution) 41. S Fulzele*, RJ Babu, E Ahaghotu, M Singh, Dermal microdialysis for quantitative measurement of local neuropeptides as markers of skin irritation in rats, AAPS Journal, Vol. 8, No. S2, Abstract T3386 (2006) (40% contribution) 42. M Singh*, S Fulzele, R Babu, L Kikwai, N Kanikkannan, Evaluation of In vitro Dermal Kinetics of Substance P Receptor Antagonist, SR 140333, AAPS Journal, Vol. 8, No. S2, Abstract M1178 (2006) (30% contribution) 43. A Chatterjee, R Babu, M Singh*. Evaluation Of A Tissue Engineered Human Skin Epiderm 3-D Culture As A Model To Study Irritation After Jet Fuel Exposure. The Toxicologist, Abstract 2004, Vol 84 (S1), March 2005 (30% contribution) 44. JB Ramapuram*#, E Ahaghotu and M Singh. Effect of methyl substitution of benzene on the percutaneous absorption and skin irritation hairless rats. The Toxicologist, Abstract 2190, Vol 84 (S1), March 2005 (50% contribution) 45. L Kikwai*, RJ Babu, R Oliveira, A Kolot, P Song, JC Ansel, C Armstrong, M Singh, In vitro and In vivo evaluation of topical formulations of Spantide II, The AAPS Journal, Vol. 7, No. S2, Abstract M1247 (2005) Won outstanding graduate student award (25% contribution) 46. L Kikwai*, RJ Babu, M Singh, Stability and Degradation Profiles of Spantide II in Aqueous Solutions, The AAPS Journal, Vol. 7, No. S2, Abstract T2137 (2005) (30% contribution) 47. RJ Babu*#, L Kikwai, R Oliveira, A Kolot, P Song, JC Ansel, C Armstrong, M Singh, Preformulation stability and percutaneous absorption of alpha-melanocyte stimulating hormone as promising anti-inflammatory agent for contact dermatitis, The AAPS Journal, Vol. 7, No. S2, Abstract R6050 (2005) (50% contribution) 48. E Ahaghotu*, RJ Babu, L Kikwai, M Singh, Dermal penetration of alpha melanocyte stimulating hormone in rats as measured by dermal microdialysis, The AAPS Journal, Vol. 7, No. S2, Abstract R6051 (2005) (40% contribution) 49. P Dayal*, RJ Babu, M Singh, Nasal permeation kinetics of melatonin formulations using Epiairway TM –AIR-100 tissue model: effect of polymers and cyclodexrins, The AAPS Journal, Vol. 7, No. S2, Abstract T2140 (2005) (30% contribution) 50. P Dayal*, RJ Babu, M Singh, The effect of polymeric gel(s) - excipient interaction on the droplet size distribution (DSD) from nasal pump sprays: the impact on DSD arising from rheological, dynamic surface tension and thermal studies, AAPS Journal, Vol. 7, No. S2, Abstract W4263 (2005) Won outstanding graduate student award (30% contribution) 51. JB Ramapuram*#, A. Chatterjee, B Locke, S Gibbs, M Singh. Studies On Percutaneous Absorption, Biophysical And Biochemical Changes In The Skin By Nonane And Dodecane In Hairless Rats, The Toxicologist, Abstract 1608, Vol 78 (S1), March 2004 (60% contribution) 52. PP Dayal*, V Pillay, RJ Babu, M Singh, The Use Of A Box-behnken Experimental Design In 14

Ramapuram CV 08/2016

The Development Of A Nasal Drug Delivery System Of Hydroxyurea: Characterization Of Viscosity, Droplet Size And Drug Release. The AAPS Journal Vol. 6, No. 4, Abstract M1236 (2004) (20% contribution) 53. RJ Babu*#, N Kanikkannan, L Kikwai, A Kundra, M Singh, Skin Permeation Enhancement, Barrier Changes And Irritation Of Sulfhydryl Compounds Using Melatonin As A Model Compound. The AAPS Journal Vol. 6, No. 4, Abstract W4223 (2004) (50% contribution) 54. RJ Babu*#, N Kanikkannan, L Kikwai, M Singh, Development Of Topical Gels Of A Novel Anti-inflammatory Peptide - Spantide-II, The AAPS Journal Vol. 6, No. 4, Abstract W4222 (2004) (50% contribution) 55. E Ahaghotu*, RJ Babu, M Singh. Skin Permeation, Retention And Irritation Responses Of Benzene, Xylene And Naphthalene In Hairless Rats. The AAPS Journal Vol. 6, No. 4, Abstract M1110 (2004) (50% contribution) 56. PP Dayal*, RJ Babu, M Singh, Characterization Of Nasal Formulations Of Melatonin For Central Brain Delivery: A Microdialysis Study In Rats, The AAPS Journal Vol. 6, No. 4, Abstract T3288 (2004) (40% contribution) 57. L Kikwai*, RJ Babu, L Jaiani, J Ansel, C Armstrong, N Kanikkannan and M Singh. Stability, Degradation Kinetics and Anti-Inflammatory Activity of Spantide-II in Irritant Contact Dermatitis Mouse Model, The AAPS Journal Vol. 6, No. 4, Abstract T3299 (2004) (50% contribution) 58. R Babu*#, L Kikwai, L Jaiani, C Armstrong, J Ansel, M Singh, Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist - Spantide II. AAPS PharmSci Vol. 5, No. 4, Abstract T2172 (2003) Won best postdoctoral fellow award (50% contribution) 59. L Kikwai*, RJ Babu, N Kanikkannan, and M Singh, Percutaneous Absorption of a Substance P Receptor Antagonist - Spantide-II from Topical Formulations, AAPS PharmSci Vol. 5, No. 4, Abstract T2187 (2003) (40% contribution) 60. L Kikwai*, RJ Babu, N Kanikkannan, and M Singh, Preformulation of Spantide II, a Promising Topical Anti-Inflammatory Agent for the Treatment of Inflammatory Skin Disorders. AAPS PharmSci Vol. 5, No. 4, Abstract T2188 (2003) (30% contribution) 61. PP Dayal*, RJ Babu, M Singh, Development of bioadhesive dosage forms of melatonin with different polymers: Release studies and characterization of the formulations by DSC. AAPS PharmSci Vol. 5, No. 4, Abstract T3017 (2003) (30% contribution) 62. PP Dayal, RJ Babu, M Singh, Evaluation of different parameters that affect droplet/particle size distribution from nasal pump sprays using Malvern Spraytec. AAPS PharmSci Vol. 5, No. 4, Abstract M1189 (2003) (30% contribution) 63. RJ Babu*#, N. Kanikkannan, L Kikwai, M Singh, Effect Of Cold Storage Of Skin On The Permeation Of Melatonin And Nimesulide, In Vitro. AAPSPharmSci Vol. 4, No. 4, Abstract R6099 (2002) (50% contribution) 64. RJ Babu*#, N Kanikkannan, L Kikwai, M Singh, Evaluation Of Sulfhydryl Compounds As Novel Skin Penetration Enhancers. AAPSPharmSci Vol. 4, No. 4, Abstract R6079 (2002) (50% contribution) 65. L Kikwai*, RJ Babu, N Kanikkannan, M Singh, Effect of Penetration Enhancers on the Percutaneous Absorption of Spantide II. AAPS Pharm. Sci., 4 (4), Abstract R6058 (2002) (10% contribution) 66. LT Jaiani*, M Sachdeva, RJ Babu, N. Kanikkannan, FJ Legat, NG Neparidze, L Kikwai, CA Armstrong, and JC Ansel, Inhibition of Allergic Contact Dermatitis by a Topically Applied SP Receptor Antagonist. J. Invest. Dermatol., 119, (1) Abstract 655 (2002) (10% contribution)

15